TaoWeave, Inc. Stock Compensation Disclosure
Note 7 - Stock-Based Compensation
2019 Equity Incentive Plan
On December 19, 2019, the Oblong, Inc. 2019 Equity Incentive Plan (the “2019 Plan”) was approved by the Company’s stockholders at the Company’s 2019 Annual Meeting of Stockholders. The 2019 Plan is an omnibus equity incentive plan pursuant to which the Company may grant equity and cash incentive awards to certain key service providers of the Company and its subsidiaries. As of December 31, 2024, and 2023, there were no remaining shares in the share pool available for new grants under the 2019 Plan.
A summary of stock compensation expense by category, for the years ended December 31, 2024, and 2023, is as follows (in thousands):
| Year Ended December 31, | ||||||||
| Stock-Based Compensation | 2024 | 2023 | ||||||
| Options | $ | 62 | $ | 124 | ||||
| RSUs | — | 380 | ||||||
| Total | $ | 62 | $ | 504 | ||||
A summary of stock compensation by department, for the years ended December 31, 2024, and 2023 is as follows (in thousands):
| Year Ended December 31, | ||||||||
| Stock-Based Compensation | 2024 | 2023 | ||||||
| Research and Development | $ | — | $ | — | ||||
| General & Administrative | 62 | 504 | ||||||
| Total | $ | 62 | $ | 504 | ||||
Stock Options
During the year ended December 31, 2024, no stock options were granted, 84 stock options were vested, and 250 vested stock options expired. During the year ended December 31, 2023, no stock options were granted, 83 stock options were vested, and 167 vested stock options expired. As of December 31, 2024, there were no stock options outstanding.
A summary of stock options expired and forfeited under our plans and options outstanding as of, and changes made during, the years ended December 31, 2024, and 2023 is presented below (in thousands except weighted-average exercise price):
| Outstanding | Exercisable | |||||||||||||||
| Number of Options | Weighted Average Exercise Price | Number of Options | Weighted Average Exercise Price | |||||||||||||
| Options outstanding and exercisable, December 31, 2022 | 417 | $ | 5,745 | 250 | $ | 8,275 | ||||||||||
| Vested | — | — | 83 | 1,950 | ||||||||||||
| Expired | (167 | ) | 11,436 | (167 | ) | 11,436 | ||||||||||
| Options outstanding and exercisable, December 31, 2023 | 250 | 1,950 | 166 | 1,950 | ||||||||||||
| Vested | — | — | 84 | 1,950 | ||||||||||||
| Expired | (250 | ) | 1,950 | (250 | ) | 1,950 | ||||||||||
| Options outstanding and exercisable, December 31, 2024 | — | $ | — | — | $ | — | ||||||||||
The intrinsic value of vested and unvested options was not significant for all periods presented. Stock compensation expense related to stock options for the year ended December 31, 2024, was $62,000, recorded as a component of General and Administrative expenses. Stock compensation expense related to stock options for the year ended December 31, 2023, was $124,000. As of December 31, 2024, there was no remaining unrecognized stock-based compensation expense for options.
Restricted Stock
As of December 31, 2024, and 2023, there were no outstanding restricted stock awards ("RSAs") or restricted stock units (“RSUs,” collectively "Restricted Stock"). There was no Restricted Stock activity or expense for the year ended December 31, 2024. During the year ended December 31, 2023, in relation to the departure of certain board members, 2 RSAs became fully vested. The 2 RSAs, along with 49 previously vested RSUs, were delivered in shares of the Company's Common Stock in accordance with the terms of the agreements. This Restricted Stock was issued in 2014 and had been fully expensed, so there was no stock compensation expense related to Restricted Stock for the year ended December 31, 2023. During the year ended December 31, 2023, 4,440 RSUs were granted to certain board members. These RSUs vested immediately upon issuance, and the stock compensation related to RSUs for the year ended December 31, 2023, was $380,000, which was included in general and administrative expenses on our Consolidated Statements of Operations.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2024 | Mar 18, 2025 | Showing above |
| 2023 | Mar 19, 2024 | |
| 2021 | Mar 29, 2022 | |
| 2018 | Mar 8, 2019 | |
About Stock Compensation Disclosures
Stock-based compensation disclosures detail the equity awards granted to employees and executives — including stock options, restricted stock units (RSUs), and performance shares — along with the valuation methods and assumptions used to expense them. This section reveals the true cost of talent retention and the alignment between management incentives and shareholder interests.
Key signals: total unrecognized compensation expense and its expected recognition period signal future earnings headwinds from already-granted awards. For stock options, examine Black-Scholes assumptions — expected volatility, risk-free rate, and expected term — as understating any of these reduces reported compensation expense. Compare stock compensation expense as a percentage of revenue against peers to assess dilution cost. Watch vesting schedules for acceleration clauses tied to change-of-control events. Performance-based awards with undemanding targets may indicate weak governance. Add back stock compensation to operating cash flow to calculate a more conservative free cash flow figure.